Study shows Pfizer's Prevnar effective in older children; Scotland calls J&J's Zytiga too expensive;

@FiercePharma: So why would Pfizer walk away from its $200M upfront for the Biocon diabetes deal? Item | Follow @FiercePharma

> Pfizer's ($PFE) Prevnar 13 vaccine proved effective in a study in children 5 to 17 years of age, which could be a new market for the company's third-best-selling product. News

> Scottish officials refused to recommend Johnson & Johnson's ($JNJ) prostate cancer pill Zytiga for use by its health service, saying its cost was not justified by its benefits. Item

> The U.K.'s cost-effectiveness gatekeepers asked for more information about long-term use of Bayer's anticoagulant Xarelto to treat and prevent certain types of blood clots. Report

> GlaxoSmithKline ($GSK) tapped India's Infosys and Britain's Fabric Worldwide for software and digital marketing services to support the drugmaker's global campaigns. Story

> Jordan's Hikma Pharmaceuticals is scouting for acquisitions in Turkey. Report

> Ranbaxy Laboratories opened its new manufacturing facility in Morocco, anticipating growth in Africa's $1 billion drug market. Article

Biotech News

@FierceBiotech: Beefed-up aspirin, charged with gas, conquers colon cancer in lab. Item | Follow @FierceBiotech

@JohnCFierce: Hwang Woo-Suk is an oddly compelling character. Convicted in a scandal that would have destroyed anyone, still moving on. Story | Follow @JohnCFierce

@RyanMFierce: FDA advisers back J&J, Pfizer efforts to start testing controversial arthritis pain meds. Story | Follow @RyanMFierce

@FierceMedDev: Consumer Reports taps ire over bad medical devices. News | Follow @FierceMedDev

> FDA scientists see improved integrity, but complaints of interference still common. News

> Regulators start thinking creatively about new approval pathway. Report

> Omeros touts promising PhIII for ophthalmology treatment. Story

> NicOx spikes on successful glaucoma drug study. More

> Pfizer walks away from $350M insulin pact with India's Biocon. News

> FDA panel backs effort to lift class hold on anti-NGF pain drugs. Item

Biotech Research News

> Stem cells end need for anti-rejection meds in some kidney transplant patients. Item

> U.K. research knocks wind out of personalized medicine push. Report

> Antibody blocks advance of Alzheimer's plaque in mice. Story

> Glaucoma-stricken rats see better, thanks to stem cells. Article

> Beefed-up aspirin, charged with gas, conquers colon cancer in lab. News

> RhoGDI2 protein hampers bladder cancer metastasis. Story

Manufacturing News

> Fire at Sandoz plant complicates drug shortages. Item

> Litigation: Sanofi, Genzyme 'negligently allowed a virus contamination in the manufacturing facility.' News

> Loss of manufacturing contract takes toll on Patheon. Report

> U.K. drug regulator asks industry to name the rules it wants to go. Story

> FDA says 5 years of Warner Chilcott's Ovcon BC pills suspect. Item

> WHO joins agencies in beefing up inspections of API facilities. Article

And Finally ... New research hints that younger patients using statins may have a lower risk of developing Parkinson's disease. Report